ImmunityBio, Inc. (IBRX)
NASDAQ: IBRX · Real-Time Price · USD
8.19
+0.12 (1.49%)
At close: Apr 23, 2026, 4:00 PM EDT
8.11
-0.08 (-0.98%)
Pre-market: Apr 24, 2026, 5:53 AM EDT
ImmunityBio Market Cap
ImmunityBio has a market cap or net worth of $8.46 billion as of April 24, 2026. Its market cap has increased by 264.35% in one year.
Market Cap
8.46B
Enterprise Value
9.06B
1-Year Change
264.35%
Ranking
Category
Stock Price
$8.19
Market Cap Chart
Since March 10, 2021, ImmunityBio's market cap has decreased from $14.82B to $8.46B, a decrease of -42.94%. That is a compound annual growth rate of -10.38%.
Market Cap History
| Date | Market Cap | % Change |
|---|---|---|
| Apr 22, 2026 | 8.33B | 327.34% |
| Dec 31, 2025 | 1.95B | 4.33% |
| Dec 31, 2024 | 1.87B | -44.23% |
| Dec 29, 2023 | 3.35B | 61.49% |
| Dec 30, 2022 | 2.08B | -14.18% |
| Dec 31, 2021 | 2.42B | -83.68% |
| Mar 10, 2021 | Upgrade Pro | Upgrade Pro |
Market Capitalization
Market capitalization, also called net worth, is the total value of all of a company's outstanding shares. It is calculated by multiplying the stock price by the number of shares outstanding.
Formula: Market Cap = Stock Price * Shares Outstanding
Full DefinitionRelated Stocks
| Company | Market Cap |
|---|---|
| Arrowhead Pharmaceuticals | 10.06B |
| Bio-Techne | 9.46B |
| Praxis Precision Medicines | 9.41B |
| ABIVAX Société Anonyme | 9.39B |
| Axsome Therapeutics | 9.38B |
| Vaxcyte | 8.77B |
| Nuvalent | 8.40B |
| Halozyme Therapeutics | 8.21B |